Progress in direct reprogramming of dopaminergic cell replacement therapy

被引：1
|
作者：
Zheng, Yuan Yuan [1 ]
Xu, Hui [2 ]
Wang, Yue Si [1 ,3 ,4 ]
机构：
[1] Binzhou Med Univ, Sch Pharm, Yantai 264003, Shandong, Peoples R China
[2] Binzhou Med Univ, Human Resources Dept, Yantai 264003, Shandong, Peoples R China
[3] Binzhou Med Univ, Med & Pharm Res Ctr, Yantai 264003, Shandong, Peoples R China
[4] Binzhou Med Univ, Yantai Key Lab Stem Cell & Regenerat Med, Yantai 264003, Shandong, Peoples R China
来源：
NEUROLOGICAL SCIENCES | 2024年 / 45卷 / 03期
关键词：
Parkinson's disease; Cell reprogramming; Induced dopamine neurons; Induced pluripotent stem cells; Induced neural stem cells; ADULT HUMAN FIBROBLASTS; PLURIPOTENT STEM-CELLS; PARKINSONS-DISEASE; NEURON CONVERSION; SOMATIC-CELLS; IN-VITRO; MOUSE; INDUCTION;
D O I：
10.1007/s10072-023-07175-z
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Parkinson's disease (PD) is a gradual neurodegenerative disease. While drug therapy and surgical treatments have been the primary means of addressing PD, they do not offer a cure, and the risks associated with surgical treatment are high. Recent advances in cell reprogramming have given rise to new prospects for the treatment of Parkinson's disease (PD), with induced pluripotent stem cells (iPSCs), induced dopamine neurons (iDNs), and induced neural stem cells (iNSCs) being created. These cells can potentially be used in the treatment of Parkinson's disease. On the other hand, this article emphasizes the limits of iPSCs and iNSCs in the context of Parkinson's disease treatment, as well as approaches for direct reprogramming of somatic cells into iDNs. The paper will examine the benefits and drawbacks of directly converting somatic cells into iDNs.
引用
收藏
页码：873 / 881
页数：9
相关论文
共 50 条
  • [1] Progress in direct reprogramming of dopaminergic cell replacement therapy
    Yuan Yuan Zheng
    Hui Xu
    Yue Si Wang
    Neurological Sciences, 2024, 45 : 873 - 881
  • [2] Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells
    Liu, Xinjian
    Li, Fang
    Stubblefield, Elizabeth A.
    Blanchard, Barbara
    Richards, Toni L.
    Larson, Gaynor A.
    He, Yujun
    Huang, Qian
    Tan, Aik-Choon
    Zhang, Dabing
    Benke, Timothy A.
    Sladek, John R.
    Zahniser, Nancy R.
    Li, Chuan-Yuan
    CELL RESEARCH, 2012, 22 (02) : 321 - 332
  • [3] Progress and Challenges of Cell Replacement Therapy for Neurodegenerative Diseases Based on Direct Neural Reprogramming
    Chen, Ying
    Pu, Jiali
    Zhang, Baorong
    HUMAN GENE THERAPY, 2016, 27 (12) : 962 - 970
  • [4] Direct cell reprogramming: approaches, mechanisms and progress
    Wang, Haofei
    Yang, Yuchen
    Liu, Jiandong
    Qian, Li
    NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2021, 22 (06) : 410 - 424
  • [5] Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease
    Chen, Weizhao
    Huang, Qiaoying
    Ma, Shanshan
    Li, Mingtao
    ACS CHEMICAL NEUROSCIENCE, 2019, 10 (02): : 839 - 851
  • [6] A promising approach to iPSC-based cell therapy for diabetic wound treatment: Direct lineage reprogramming
    Li, Shuang
    Li, Qin
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2014, 393 (1-2) : 8 - 15
  • [7] Cell reprogramming therapy for Parkinson's disease
    Dong, Wenjing
    Liu, Shuyi
    Li, Shangang
    Wang, Zhengbo
    NEURAL REGENERATION RESEARCH, 2024, 19 (11) : 2444 - 2455
  • [8] Direct Cardiac Reprogramming Progress and Challenges in Basic Biology and Clinical Applications
    Sadahiro, Taketaro
    Yamanaka, Shinya
    Ieda, Masaki
    CIRCULATION RESEARCH, 2015, 116 (08) : 1378 - 1391
  • [9] MicroRNA Roles in Cell Reprogramming Mechanisms
    Pascale, Emilia
    Caiazza, Carmen
    Paladino, Martina
    Parisi, Silvia
    Passaro, Fabiana
    Caiazzo, Massimiliano
    CELLS, 2022, 11 (06)
  • [10] Direct cell reprogramming for tissue engineering and regenerative medicine
    Grath, Alexander
    Dai, Guohao
    JOURNAL OF BIOLOGICAL ENGINEERING, 2019, 13 (1)
12345